Slowed Decline of Cognitive Functions ity Assessment for Dementia (DAD) rating scale by interviewing caregivers in a double-blinded manner (Gauthier and Capacities of Daily Living
AD patients who generated antibodies against ␤-amyet al., 1997). The DAD assesses activities of daily living including initiation, planning, and organization; perforloid (n ϭ 19) performed markedly better on the Mini Mental State Examination (MMSE) 8 months and 1 year mance in eating, bathing, grooming, dressing, and toileting; and telephone communication, paying bills, cookafter the immunization, as compared to control patients (n ϭ 9, p ϭ 0.008, ANOVA) ( Figure 2A) . As compared to ing, and shopping. Performance in the DAD was significantly better in patients who generated antibodies baseline, the patients who generated antibodies against ␤-amyloid remained unchanged after 1 year (Ϫ1.4 Ϯ 3.5, against ␤-amyloid, as compared to control patients (Figure 2B ). After 12 months, patients who generated antimean Ϯ SD n.s., median ϭ Ϫ1.0). Patients in the control group worsened significantly by Ϫ6.3 Ϯ 4.0 MMSE bodies against ␤-amyloid declined by Ϫ2.9 Ϯ 3.8 of 40 points on the DAD, as compared to Ϫ8.7 Ϯ 10.0 in points (mean Ϯ SD, median ϭ Ϫ5.0; p Ͻ 0.01, Wilcoxon). This magnitude of progression of dementia is clinically control patients (p ϭ 0.030, ANOVA) or, in percent of applicable questions, by Ϫ6.1% Ϯ 9.0% versus relevant, and it is somewhat higher than rates of decline known for the natural history of AD of Ϫ3.9 Ϯ 3.7 MMSE Ϫ20.1% Ϯ 23.4%, respectively (p ϭ 0.039, ANOVA). Thus, the cognitive stabilization translated into relepoints per year, but both our mean and median values are well within one standard deviation of published data vance for daily life. To determine whether the clinical outcome was related to TAPIR scores, we grouped the patients according to To determine whether beneficial effects were also noted by the patients' caregivers, we applied the Disabilthe magnitude of increases in TAPIR scores and ob- Only two-thirds of the study patients in either group were able to complete this task. Performance of the patients who generated antibodies against ␤-amyloid (n ϭ 13) was significantly better (*p ϭ 0.029, ANOVA) as compared to control patients (n ϭ 5). tained the following three groups: no increase (n ϭ 9), ␤-amyloid had progressed to severe dementia (p Ͻ 0.01, 2 ϭ 7.25, d.f. ϭ 1; Figure 2D ). Moreover, 21% (4 of 19) intermediate increase (n ϭ 13), and strong increase (n ϭ 6) ( Figure 2C 
Antibodies against ␤-Amyloid Can Reach the Brain
We had available 20 paired CSF samples obtained both at baseline and after 1 year. We found that immune CSF of four patients contained antibodies against ␤-amyloid ( Figure 1B ), demonstrating the principal ability for the antibodies to reach the CSF compartment. CSF/serum ratios for albumin were normal in the patients with CSF Figure 4C ), arguing against 6), naming (0.1 Ϯ 0.7, n ϭ 19 versus 0.7 Ϯ 1.0, n ϭ 9), the possibility that sequestration of serum A␤ is an unverbal fluency (Ϫ3.6 Ϯ 5.1, n ϭ 18 versus Ϫ5.9 Ϯ 4.3, derlying principle of the therapeutic effects observed n ϭ 8), and CGIC (Ϫ0.1 Ϯ 0.7, n ϭ 18 versus Ϫ1.1 Ϯ here. We do not know whether brain ␤-amyloid load was 1.0, n ϭ 8).
reduced in our study patients; in vivo imaging techniques will be required to answer this question. Sustained Increases in Serum Antibodies against A␤ Discussion The group of patients who generated antibodies against ␤-amyloid showed a marked and long-lasting increase
Here we report the results of our TAPIR analysis applied to the Zurich cohort of 30 patients who participated in in serum antibodies against aggregated A␤ 42 in both IgG ( Figure 3A) and IgM ( Figure 3B ated by significantly better performance in activities of adequately by preparations of synthetic A␤ on ELISA plates. Together, the data underscore the importance of using appropriate assays for antibody analyses, and they suggest using TAPIR scores instead of ELISA titers for the analysis of responders. These data also demonstrate the necessity for carefully selecting therapeutically relevant epitopes within ␤-amyloid and its constituents for the future development of immunotherapy for AD. The observed clinical differences among AD patients with and without an immune response were unrelated to the AChEI treatments, because patients in both groups were on stable dosages of AChEI before and during this trial. These data therefore support the possibility that the therapeutic effects of antibodies against ␤-amyloid and AChEI are additive. For the formal test of this possibility, however, control groups without AChEI treatments are required. Other factors that could potentially affect rates of progression of dementia, including age, gender, medication, and head trauma, were either excluded by the selection criteria or were distributed evenly among the groups. The ApoE genotype affects the risk for getting AD as well as the age of onset, but not the rate of cognitive decline once the disease has started (Growdon et al., 1996). Nevertheless, the distribution of the common ApoE genotypes was equal among the groups man's rho. All p values reported are two-sided. Changes in neuropsychological test scores (three data collection time points) were For comparisons with a standard curve obtained by diluting human CSF from a responder, both preimmune and immune sera were analyzed by observed cases analyses (OC). Changes in serum titers and plasma A␤ levels (ten data collection time points) were analyzed used at 1:50 dilutions and categorized by two independent, blinded raters into the following five immunoreactivity scores: absent immuby intention to treat (ITT) analysis; missing values were interpolated between visits and last values were carried forward. noreactivity (-); weak immunoreactivity corresponding to 1:10,000 (ϩ); moderate, 1:5,000 (ϩϩ); strong, 1:1,000 (ϩϩϩ); and very strong, 1:500 (ϩϩϩϩ). To determine the increase in immunoreactivity durAcknowledgments ing treatment, the preimmune immunoreactivity scores were subtracted from the immune scores to generate the following group:
The preparations of active vaccine and placebo were administered no increase, n ϭ 10 (n ϭ 9 observed cases) in the control group. In to the patients within the ELAN/Wyeth-Ayerst AN1792(QS-21) trial. the group of patients who generated antibodies against ␤- The authors declare that they have no competing financial interests related to Elan/Wyeth-Ayerst.
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